AzTrials
AzTrials

PulpitisNCT06938191

Comparison of Aquaporin -4, -5, -9 and IL-8 Levels in GCF, Dentin Fluid and Pulp Samples

An observational study of Pulpitis and Pulpitis - Irreversible, run by Kırıkkale University.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This study aimed to compare the changes in AQP -4, -5, -9, and IL-8 levels in pulp tissue, GCF, and dentin fluid samples routinely obtained during the treatment of healthy and symptomatic teeth diagnosed with irreversible pulpitis and investigate whether there is a correlation between them. Read more about this study

Who is it for?
Ages 18 to 64 yearsHealthy volunteers can take part
How many people
70 participants
Where
No sites listed yet
Study dates
Dec 2025to 12 Sep 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 64 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Study population: This study will include patients aged 18-64 years who present to the Department of Endodontics, Faculty of Dentistry, Kırıkkale University, with an indication for root canal therapy and are diagnosed with either a healthy pulp status (Group 1) or symptomatic irreversible pulpitis (Group 2).

Who may be able to join

  • Patients aged 18 to 64 years.
  • Patients without any known systemic disease.
  • Patients requiring root canal treatment for prosthetic purposes (Healthy pulp group).
  • Patients with third molars (wisdom teeth) indicated for extraction due to orthodontic or other clinical reasons (Healthy pulp group).
  • Patients diagnosed with symptomatic irreversible pulpitis based on the criteria established by the American Association of Endodontists (AAE) (Symptomatic irreversible pulpitis group).
  • Patients scheduled for routine root canal treatment at the Department of Endodontics, Faculty of Dentistry, Kırıkkale University.
  • Patients who have provided written informed consent to participate in the study.

Who cannot join

  • Patients with any known systemic disease.
  • Pregnant women or those suspected of being pregnant.
  • Patients who have used antibiotics, anti-inflammatory drugs, or antidepressants within the past 4 weeks.
  • Patients with significant dental plaque or calculus, gingival redness or bleeding, severe gingivitis, generalized periodontitis, or periodontal pockets deeper than 4 mm.
  • Patients with teeth showing internal or external root resorption.
  • Patients for whom complete rubber dam isolation cannot be achieved.
Show all 9Show fewer
  • Patients with teeth exhibiting signs of necrosis, apical lesions, swelling, or presence of a sinus tract.
  • Patients with immature teeth presenting open apices.
  • Patients with third molars (wisdom teeth) that are not fully erupted or have been previously diagnosed with pericoronitis.

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

ALİ ERDEMİR, PROF. contact

+905325650065

erdemirali@hotmail.com

About this study

Official title: Comparison of Aquaporin -4, -5, -9 and IL-8 Levels in Gingival Crevicular Fluid, Dentin Fluid and Pulp Samples of Healthy and Acute Irreversible Pulpitis Teeth

This study aimed to compare the changes in AQP -4, -5, -9, and IL-8 levels in pulp tissue, GCF, and dentin fluid samples routinely obtained during the treatment of healthy and symptomatic teeth diagnosed with irreversible pulpitis and investigate whether there is a correlation between them.

A total of 70 patients aged 18-64 years with healthy (Group 1) and symptomatic irreversible pulpitis (Group 2) diagnosed at Kırıkkale University, Faculty of Dentistry, Department of Endodontics who will undergo routine root canal treatment will be included in the study, with a minimum of 35 participants for each group. Before starting treatment, DOS samples will be taken from healthy, symptomatic, irreversible pulpitis-diagnosed teeth and teeth contralateral to these teeth. A dentin fluid sample will be taken by holding the membrane on the dentin surface, and the pulp tissue will be removed and transferred to Eppendorf tubes. The treatment process will be completed by applying routine root canal procedures to the teeth. The samples' Aquaporin -4, -5, -9, and IL-8 levels will be analyzed by specific enzyme-linked immunosorbent assay (ELISA).

Read the detailed description

A total of 70 healthy (Group 1) and symptomatic irreversible pulpitis (Group 2) patients aged 18-64 years, who will undergo routine root canal treatment at Kırıkkale University, Faculty of Dentistry, Department of Endodontics, will be included in the study, with a minimum of 35 participants for each group. Before starting treatment, GCF samples will be taken from healthy, symptomatic, irreversible pulpitis-diagnosed teeth and teeth contralateral to these teeth. The tooth from which the GCF sample will be taken will be isolated with cotton pellets. After the supragingival plaque is carefully removed with a curette without touching the gums, the tooth will be dried with light air pressure for 10 seconds and periopaper strips will be placed in the gingival sulcus until resistance is felt. The periopaper strips will be removed from the gingival sulcus after 1 minute. While taking the samples, care should be taken not to contaminate with blood and saliva; contaminated samples will be repeated. The amount of GCF will be measured and recorded using the periotron device. The microliter equivalents of the values measured on the Periotron device will be recorded. Periopaper strips will be placed in 1.5 cc sterile eppendorf tubes. Gingival index and pocket depth measurements will be performed after GCF samples are taken to prevent irritation of periodontal tissues and blood contamination. Patients with a pocket depth of more than 4 mm will be excluded from the study.

After anesthesia with 1.8 ml articaine HCl containing 1:100000 epinephrine, the teeth will be isolated with rubber-dam disinfected with 70% alcohol. After disinfection of the tooth crowns and surrounding area with 30% hydrogen peroxide and 2.5% NaOCl, caries and existing restorations, if any, will be removed. In teeth with normal pulp, dentin fluid samples will be taken from the dentin cavity approximately 2 mm away from the pulp as calculated on radiographs. The exposed hard dentin surface will be dried with compressed air. Using a sterile press, 1 membrane per tooth will be applied to the exposed dentin for 1 minute and 1.5 mL will be transferred to a sterile eppendorf tube.

The pulp chamber ceiling will be removed with a No. 14 steel rond milling cutter using a micromotor. Using a sterile excavator and tirnerf, healthy and inflamed pulp samples will be removed and transferred to sterile eppendorf tubes to which 200 μl of Phosphate Buffer (PBS) pH:7.2 will be added.

While collecting the samples, care should be taken not to contaminate them with blood and saliva; GCF and dentin fluid samples with suspected contamination will be repeated. Patients with samples with contamination of pulp tissue or deterioration in storage conditions will be excluded from the study. GCF, dentin fluid and pulp tissue samples transferred to a 1.5 mL sterile eppendorf tube labeled with a code assigned to the patient with diagnosis and date, with low protein binding, kept immediately on ice, transferred to a freezer and kept at -20 °C. Samples will be transported from the clinic to the freezer at -80°C and stored in a freezer at -80°C to prevent denaturation until further analysis.

The treatment process will be completed by applying routine root canal procedures to the teeth. Teeth in the healthy pulp group with an indication for extraction will be extracted after the samples are taken, subjected to normal extraction procedures.

Aquaporin -4, -5, -9 and IL-8 levels of the samples will be analyzed by specific enzyme-linked immunosorbent assay (ELISA).

Data will be analyzed in computer environment with SPSS 28.0 (Statistical Package for the Social Sciences, NY, USA) statistical package program. Results will be evaluated at 95% confidence interval and p<0.05 significance level.

Keywords
healthy pulp, pulpitis, irreversible pulpitis, aquaporin-4, IL-8, aquaporin-5, aquaporin-9
Medical subject headings
Pulpitis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT06938191
Study groupRoleWhat they receive
healthy pulp groupMinimum 35 participants Procedure: Collection of GCF samples using periopaper. Collection of dentinal fluid using cellulose membrane. Collection of pulp tissue samples using a tirnerf.
irreversible pulp groupMinimum 35 participants Procedure: Collection of GCF samples using periopaper. Collection of dentinal fluid using cellulose membrane. Collection of pulp tissue samples using a tirnerf.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Aquaporin-4, Aquaporin-5 and Aquaporin-9 expression levels in pulp tissue in dentin fluid and GCF samples

    Levels of IL-8, AQP-4, AQP-5 and AQP-9 will be measured in dentin fluid, GCF and pulp tissue samples obtained during routine root canal treatment. The analysis will be performed using ELISA. The aim is to compare the expression levels between healthy individuals and patients with irreversible pulpitis.

    Measured: Immediately after the procedure

Secondary outcomes (1)
  1. Correlation analysis between Aquaporin (AQP-4, AQP-5, AQP-9) and IL-8 levels in pulp tissue, dentin fluid, and GCF samples

    The study will assess the correlation between Aquaporin isoforms (AQP-4, AQP-5, and AQP-9) and IL-8 concentrations within and between two groups: healthy individuals and patients diagnosed with irreversible pulpitis. Correlation analyses will be conducted separately for each group, as well as comparatively across groups, using appropriate statistical methods to explore intra- and intergroup relationships among biomarkers in pulp tissue, dentin fluid, and GCF samples.

    Measured: Immediately after the procedure

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Apr 2025
  2. Study startDec 2025 (estimated)
  3. Primary completionFeb 2026 (estimated)
  4. Study completion12 Sep 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Cross-sectional
Enrolment
70 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06938191
Sponsor's protocol ID
2025/05-2025.03.02
Status last verified
Aug 2025
First submitted
11 Apr 2025
Last updated
1 Dec 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Pulpitis and Pulpitis - Irreversible, run by Kırıkkale University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 1 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact ALİ ERDEMİR, PROF. (+905325650065, erdemirali@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Aquaporin-4, Aquaporin-5 and Aquaporin-9 expression levels in pulp tissue in dentin fluid and GCF samples (time frame: Immediately after the procedure). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Dec 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in